



Corporate Presentation

Nasdaq: PLXP

CONFIDENTIAL

Forward-looking Statements
















This presentation includes or incorporates by reference statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements include, but are not limited to information or assumptions about expenses, capital and other expenditures, financing plans, capital structure, cash flow, liquidity, management's plans, goals and objectives for future operations and growth. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases beyond our control and which could cause actual performance or results to differ materially from those expressed in or suggested by forward-looking statements.

Important factors that could cause such differences include, but are not limited to (i) our ability to bring both VAZALORE™ 81 mg and VAZALORE 325 mg to market-readiness; (ii) our ability to maintain regulatory approval of VAZALORE 325 mg or obtain and maintain regulatory approval of VAZALORE 81 mg and any future product candidates; (iii) the benefits of the use of VAZALORE; (iv) our ability to successfully commercialize our VAZALORE products, or any future product candidates; (v) the rate and degree of market acceptance of our VAZALORE products or any future product candidates; (vi) our ability to scale up manufacturing of our VAZALORE products to commercial scale; (vii) our ability to successfully build a specialty sales force and commercial infrastructure or collaborate with a firm that has these capabilities; (viii) our ability to compete with companies currently producing NSAIDs and other products; (ix) our reliance on third parties to conduct our clinical studies; (x) our reliance on third-party contract manufacturers to manufacture and supply our product candidates for us; (xi) our ability to retain and recruit key personnel, including development of a sales and marketing function; and (xii) our ability to obtain and maintain intellectual property protection for our VAZALORE products or any future product candidates.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONFIDENTIAL

PLx Pharma Management Team

Name	Experience
 <p>Mike Valentino <i>Executive Chairman of the Board</i></p>	<p>35+ years CEO and senior management with successful OTC and Rx brands (OTC brand, Mucinex®: \$2.3 billion exit in 4.5 years)</p>     
 <p>Natasha Giordano <i>President and CEO</i></p>	<p>25+ years CEO and senior management commercialization experience</p>       
 <p>Rita O'Connor, CPA <i>Chief Financial Officer Head of Mfg & Supply Chain</i></p>	<p>25+ years finance leadership in public and private Rx and OTC companies</p>   
 <p>Steven Valentino <i>VP, Trade Sales</i></p>	<p>25+ years in OTC and consumer healthcare including Rx-to-OTC switches, brand management, trade sales</p>    
 <p>Joanne Cotignola <i>VP, Marketing</i></p>	<p>25+ years in OTC healthcare brand management at public and private companies</p>    

CONFIDENTIAL

OUR MISSION

PLx Pharma is focused on improving the performance of established therapeutic agents with its proprietary PLxGuard™ targeted drug delivery platform

We are driven to transform the standard of care for millions of patients

CONFIDENTIAL

PLxGuard™ – Innovative Drug Delivery Platform

Designed to improve drug absorption and reduce risk of stomach erosions and ulcers

Novel mechanism of delivery enables strong patent life for multiple APIs

Our Lead Product is VAZALORE™



NOW
FDA
APPROVED!

First and only FDA-approved liquid-filled aspirin capsule for over 40 million patients at risk for vascular events

Fast and reliable platelet inhibition addressing the limitations of the current standard of care enteric-coated (EC) aspirin*

Fewer gastric erosions and ulcers than immediate release (IR) aspirin as seen in clinical trials**

Large OTC opportunity with a \$10 billion retail market

World-renowned Scientific Advisory Board chaired by Drs. Deepak Bhatt & Dominick Angiolillo

* Clinically shown on VAZALORE 325 mg after 3 days of treatment

** Clinically shown on VAZALORE 325 mg after 7 days of treatment

CONFIDENTIAL



Advancing the Standard of Care

CONFIDENTIAL

History of Aspirin Innovation




1985

FDA expands the use of aspirin for secondary prevention¹

FDA professional labeling states "...enteric coated aspirin products are erratically absorbed from the GI tract"²

1940s

Enteric Coating patents issued




1800s

Acetylsalicylic acid extracted from willow bark



C3000 – 1500 BC

Willow tree used as medicine by ancient civilizations



80 years since last innovation

Advancing the SOC: VAZALORE

Improved performance:

- Delivers the life-saving drug aspirin in a novel liquid-filled capsule
- Designed to bypass the stomach and be absorbed in the intestine
- Fast, reliable, predictable antiplatelet therapy*
- Lower risk for stomach erosions and ulcers vs. IR aspirin**

2021

VAZALORE: First and only FDA-approved liquid-filled aspirin capsule expected U.S. launch

CONFIDENTIAL

VAZALORE Novel Mechanism of Delivery

VAZALORE is a liquid-filled aspirin capsule

1 Helps Protect the Stomach


Capsule rapidly dissolves and releases the lipid-aspirin complex which stays intact in the stomach

2 Targeted Release in the Duodenum

- Higher pH dissociates complex
- Aspirin is free for absorption

3 Fast and Reliable Absorption

Predictable bioavailability as confirmed by two separate clinical studies on VAZALORE 325 mg ^{1,2}



FDA professional labeling states "...immediate release aspirin is well and completely absorbed from GI tract"³

CONFIDENTIAL

Time to Complete Antiplatelet Effect¹

Objectives:


- Determine whether formulation dependent bioavailability mediates aspirin non-responsiveness

Methods:

- Randomized, blinded, triple crossover study
 40 obese diabetic patients receiving 3 daily doses of:
 - Plain aspirin 325 mg
 - VAZALORE 325 mg
 - EC aspirin 325 mg

Primary Endpoint:

- Time to >99% Thromboxane B₂ (TXB₂) inhibition





Vazalore achieved 99% TXB₂ inhibition significantly faster than EC aspirin

CONFIDENTIAL

¹ Bhatt DL, et al. Enteric Coating and Aspirin Non-Responsiveness in Patients With Type 2 Diabetes Mellitus. *J Am Coll Cardiol* 2017 Feb; 69(6):603-12

PK/PD Comparison of IR, EC & VAZALORE¹



CONFIDENTIAL

Endoscopic Assessment: Upper GI Damage Comparison to IR ASA¹

Objectives:

- Determine whether a novel, lipid-based aspirin formulation can reduce gastric erosions and ulcers


Methods:

- Randomized, blinded, multi-center study in 204 healthy volunteers:
 - 7 days of either aspirin or VAZALORE 325 mg
 - Endoscopy performed at Baseline and Day 7
 - Centralized, blinded endoscopic adjudication

Primary Endpoint:

- Incidence of gastroduodenal erosions or ulcers at 7 days

PL2200 = VAZALORE™ 325 mg



Gastroduodenal mucosal damage at 7 days:

(a) % of subjects with erosions and/or ulcers (b) % of subjects with ulcers

VAZALORE caused significantly fewer erosions and ulcers than IR aspirin

47% lower risk of erosions or ulcers (NNT=5)
71% lower risk of ulcers (NNT=8)

CONFIDENTIAL

VAZALORE: Miracles of Aspirin

Now in an FDA-Approved Novel Liquid-filled Capsule



**NOW
FDA
APPROVED!**

VAZALORE achieved 99% thromboxane B2 inhibition **significantly faster** than EC aspirin*

Absorption with VAZALORE was **5X as high** as EC aspirin*

VAZALORE provided complete antiplatelet effect (99% TxB2) for **almost twice** as many patients as EC aspirin*

VAZALORE caused **significantly fewer** erosions and ulcers than IR aspirin**

* Clinically shown on VAZALORE 325 mg after 3 days of treatment in obese diabetic patients

** Clinically shown on VAZALORE 325 mg after 7 days of treatment

CONFIDENTIAL

VAZALORE U.S. Market Opportunity: \$10 Billion

	Vascular Patients	Diabetic Patients	TOTAL
Target Population ¹ (millions)	27.2	15.6	42.8
Retail Market Size (billions)	\$6.4	\$3.6	\$10.0



VAZALORE™

Market Share	Factory (millions)	Retail (millions)
1%	\$70	\$100
5%	\$350	\$500

- Vascular Patients: patients with Atherosclerotic Cardiovascular Disease (ASCVD) defined by having a previous event such as heart attack or stroke or a previous procedure such as cardiac stent, bypass operation, carotid operation or who have imaging evidence of significant vascular disease such as ultrasound, angiogram, etc.
- Diabetic Patients: Patients with diabetes but without evidence of ASCVD who are candidates for aspirin therapy.

CONFIDENTIAL

Leveraging Changing Market Dynamic




Consumers
Embracing Online shopping



Cardiologists
Integrating Virtual Engagement
(i.e., Medical Conferences, Patient Care, etc.)

**COVID-19 Impact
is Far-Reaching**




**PLx Embracing New
Ways to Reach the
Market**



Retailers
Building Capabilities to
Accommodate New Behavior


CONFIDENTIAL

VAZALORE Launch Plan Focused on Consumers and HCPs



CONFIDENTIAL

VAZALORE Launch Timeline



- Submitted both VAZALORE sNDA filings (325 mg and 81 mg) end of October 2020
- Received user fee goal date from FDA for end of February 2021
- FDA Approved VAZALORE 325 mg and 81 mg in February 2021
- Targeting launch of both VAZALORE 325 mg and 81 mg dose strengths in third quarter 2021

CONFIDENTIAL

Pipeline Leverages PLxGuard Platform Technology

PLxGuard applicable to a <i>variety of APIs</i>			Pre-Clinical	Phase 1	Phase 2	Phase 3
Product Candidate	Type	Size				
VAZALORE liquid-filled aspirin capsules Pain & Physician-directed Indications	OTC	42.8M Patients at High Risk for Vascular Events	VAZALORE 325 mg and 81 mg FDA APPROVED			
PL1200 Ibuprofen, 200 mg* Pain, Inflammation and Fever	OTC	25.3M Suffer Daily Pain				
Other NSAIDs e.g. Indomethacin**, Diclofenac**	OTC & Rx	25.3M Suffer Daily Pain				
National Cancer Institute Grant PLx Formula in test with Colorectal Cancer Patients**	OTC & Rx	1.3M Sufferers of Colorectal Cancer				

Clinical (*) and pre-clinical (**) proof-of-concept studies

CONFIDENTIAL

Independent Board of Directors & Scientific Advisory Board

Board of Directors

Director	Experience
 Gary S. Balkema	<ul style="list-style-type: none"> Former global head of Bayer Healthcare LLC and Worldwide Consumer Care Division Prior VP and General Manager for American Cyanamid Co.'s Lederle Consumer Health Division
 Tony Bartsh	<ul style="list-style-type: none"> Portfolio manager and partner at Park West Asset Management Former investment analyst at Emrose Capital and Crosslink Capital
 Kirk Calhoun	<ul style="list-style-type: none"> Former audit committee chair, Adams Respiratory Former partner, Ernst & Young LLP
 Bob Casale	<ul style="list-style-type: none"> Former Adams Respiratory COO (Mucinex®, Adams' IPO and \$2.3 billion sale) Former senior manager at Pfizer, Warner Lambert and CEO of Scerene Healthcare
 John W. Hadden II	<ul style="list-style-type: none"> SVP of Operations Secura Bio, Inc. Former CEO of IRX Therapeutics and former healthcare investment banker at JP Morgan & Co.

Scientific Advisory Board

 Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Executive Director of Interventional CV Programs Brigham and Women's Hospital Heart & Vascular Center Professor of Medicine, Harvard Medical School Boston, MA, USA	 Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Program Director, Interventional Cardiology Fellowship Professor of Medicine, Director, Cardiovascular Research University of Florida College of Medicine-Jacksonville Jacksonville, FL, USA	 P. Gabriel Steg, MD, FESC, FACC Director of the Coronary Care Unit, Hôpital Bichat-Claude Professor of Cardiology, Univ. Paris VII - Denis Diderot Professor at the National Heart and Lung Institute, Imperial College, London, UK Paris, FRANCE	 Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, FSCAI Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute at Mount Sinai School of Medicine	 Byron Cryer, MD Associate Dean for Faculty Diversity and Development Professor of Medicine, UT Southwestern Medical School Dallas, TX, USA	
 James M. Scheiman, MD David Stone Prof of Internal Medicine Chief, Division of Gastroenterology and Hepatology Digestive Health Service Line Medical Director, University of Virginia Health System, University of Virginia Charlottesville, VA, USA	 Mark J. Alberts, MD Physician-in-Chief Ayer Neuroscience Institute Hartford HealthCare Chief of Neurology Hartford Hospital, Professor of Neurology UConn School of Medicine	 Jayne Prats, PhD Elysia Medical Scientific Solutions Boston, MA, USA	 Efthymios N. Deliargyris, MD, FACC, FESC, FSCAI Chief Medical Officer CytoSorbents Corporation Monmouth Junction, NJ	 Carey Kimmelstiel, MD, FACC, FACP, FSCAI Director, Catheterization Laboratory and Interventional Cardiology, Tufts Medical Center Professor of Medicine, Tufts University School of Medicine Boston, MA, USA	 Todd K. Rosengart, MD Professor and Chairman, DeBakey-Bard Chair of Surgery Michael E. DeBakey Department of Surgery Baylor College of Medicine Houston, TX, USA

CONFIDENTIAL



Thank
You

CONFIDENTIAL